Degenerated intervertebral disc tissue

Degenerated intervertebral disc tissue represents a pathological state of the fibrocartilaginous structures between the vertebrae, characterized by significant biochemical and structural alterations including dehydration of the nucleus pulposus and degradation of the extracellular matrix. Biologically, the disc functions as a mechanical shock absorber and provides spinal flexibility, but degeneration leads to the loss of these functions and the ingrowth of nociceptive nerves and blood vessels, which are major sources of chronic low back pain. While not a singular molecular target, this tissue is the primary site for regenerative and symptomatic therapies that aim to restore disc height, hydration, and mechanical integrity. Therapeutic approaches include the use of growth factors (e.g., BMP-7, GDF-5), senolytics to clear aged cells, and anti-inflammatory agents to inhibit catabolic enzymes such as MMPs and ADAMTS. Challenges in drug development for this tissue are significant due to its extreme avascularity and the hostile, acidic, and hypoxic microenvironment that limits the survival and efficacy of administered biologics and small molecules.

Other names

Degenerative disc tissueDegenerated intervertebral discDegenerated IVDIntervertebral disc degenerationDiscogenic tissue

Proteolysis of the nucleus pulposus to reduce disc pressure, stimulation of extracellular matrix (ECM) synthesis via anabolic growth factors, inhibition of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1beta), and selective clearance of senescent cells (senolysis) to improve tissue homeostasis.